胰切除术中放疗用于交界可切与局部晚期胰腺癌的倾向匹配分析
该单中心回顾性队列研究纳入2010–2024年在新辅助治疗后行胰切除术的交界可切/局部晚期胰腺导管腺癌患者,2021年起采用术中放疗,经1:1倾向评分匹配后比较100例(各50例)。
要点
- 术中放疗与局部复发风险降低独立相关(HR 0.46,95%CI 0.22–0.98)。
- 主要并发症相当(10%比21%),远处无复发生存无差异。
核心结论
- 术中放疗与交界可切/局部晚期胰腺导管腺癌患者局部控制改善相关,且未增加并发症,需前瞻性验证。
研究设计与样本
- 2021年机构采用术中放疗后,按人口学、肿瘤大小、治疗和合并症进行1:1倾向评分匹配,匹配后分析100例(术中放疗50例、对照50例),中位随访21.2个月。
主要发现
- 匹配后两组肿瘤生物学与切除质量均衡(R0为88%比90%)。
- 远处无复发生存无差异,主要并发症相当(10%比21%)。
临床怎么用
- 对交界可切/局部晚期胰腺导管腺癌新辅助治疗后行胰切除术者,可考虑术中放疗以改善局部控制,且不增加主要并发症。
局限性
- 回顾性单中心设计,样本量有限(匹配后100例),中位随访21.2个月,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Borderline resectable and locally advanced pancreatic ductal adenocarcinoma remains associated with high local recurrence despite modern neoadjuvant therapy and surgery. Intraoperative radiation therapy enables targeted radiation delivery to the tumor bed while minimizing exposure to surrounding structures, yet its oncologic benefit in pancreatic ductal adenocarcinoma remains unclear. This study evaluated whether intraoperative radiation therapy improves survival and recurrence outcomes in borderline resectable/locally advanced pancreatic ductal adenocarcinoma patients undergoing pancreatectomy after neoadjuvant therapy. METHODS: Retrospective cohort study (Jan 2010-Dec 2024) of borderline resectable/locally advanced pancreatic ductal adenocarcinoma patients undergoing pancreatectomy with or without intraoperative radiation therapy at a single high-volume center. Following institutional adoption of intraoperative radiation therapy in 2021, propensity score matching (1:1) was adjusted for demographics, tumor size, therapies, and comorbidities. The primary endpoint was recurrence-free survival, evaluated as local recurrence-free survival and distant recurrence-free survival. Secondary endpoints included overall survival and major complications. RESULTS: After matching, 100 patients (50 intraoperative radiation therapy, 50 controls) with a median follow-up of 21.2 months were analyzed. Groups were balanced for tumor biology and resection quality (88% vs 90% R0). Intraoperative radiation therapy was associated with improved local recurrence-free survival at 24 months (79% vs 53%; P = .049) and reduced local recurrence risk (hazard ratio, 0.46; 95% confidence interval, 0.22-0.98; P = .043). Overall survival at 24 months favored intraoperative radiation therapy (58% vs 43%; log-rank P = .058), with an independent association on multivariable analysis (hazard ratio, 0.57; P = .038). Distant recurrence-free survival did not differ. Major complications were comparable (10% vs 21%). CONCLUSION: Intraoperative radiation therapy was associated with improved local control in borderline resectable/locally advanced pancreatic ductal adenocarcinoma without added morbidity, warranting prospective validation.
引用
- Verastegui A, Thiyagarajan SK, Rutenberg M, et al. Intraoperative radiation therapy during pancreatectomy for borderline and locally advanced pancreatic cancer: A propensity-matched analysis. Surgery. 2026. PMID: 42224965. doi:10.1016/j.surg.2026.110293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。